chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Initial report received from a nurse on 18 Mar 2010: This patient inadvertently administered FLUVIRIN (expiry date: Feb 2010) (Batch no.: 1009234P), intramuscular, expired vaccine on 18 Mar 2010. No adverse effects were reported after administration. The outcome of the event was not reported.
Information has been received from a registered nurse concerning a 15-month-old male with no pertinent medical history or allergies, who on 17-JAN-2008 was vaccinated subcutaneously with a first 0.5 mL dose of varicella virus vaccine live (Oka/Merck) (lot# 658182/1559U). Concomitant therapy included a dose of ActHIB. On 02-Feb-2008, the patient developed a rash on his lower extremities. The patient was seen in the office on 04-FEB-2008, and was diagnosed with chicken pox. The R.N. reported that there were greater than 50 lesions. There were no laboratory or diagnostic studies performed. The outcome was reported as not recovered. No product quality complaint was involved. Additional information has been requested. This is in follow-up to report(s) previously submitted on 5/16/2008. Follow-up information was received concerning a male with no pre-existing allergies, birth defects or medical conditions. On 17-Jan-2008 the patient was vaccinated in the left leg with a first dose of VARIVAX (Merck) (lot# 658182/1559U). There was no illness at the time of vaccination. On 04-Feb-2008, previously reported as 02-Feb-2008, the patient developed greater than 50 "eryth" papules in clusters/crops on the lower extremities. BENADRYL was administered. On an unspecified date, the patient recovered. Additional information is not expected.
Pinpoint raised, slightly red rash developed slowly on same day of vaccination- may be itchy. 9/29 Temp 102 R, 10/1 102.5. Bulging eardrum also 10/1 placed on amoxicillin 1 1/4 tsp BID X 10 days plus Benadryl (rash became systemic head to toes) Benadryl is relieving symptoms.
Patient was administered with vaccine that was beyond use date after the thaw process; This spontaneous case was reported by a paramedic and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Patient was administered with vaccine that was beyond use date after the thaw process) in a 48-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030h21b) for COVID-19 prophylaxis.     It was unknown if patient had been diagnosed with or tested positive for COVID-19, nor if patient had chronic or long lasting health conditions. It was unknown if patient had any acute illness at the time of vaccination and up to one month before.     On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .25 milliliter. On an unknown date, the patient experienced EXPIRED PRODUCT ADMINISTERED (Patient was administered with vaccine that was beyond use date after the thaw process). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Patient was administered with vaccine that was beyond use date after the thaw process) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   The patient age was reported as 48 years 11 months. No concomitant medications were reported.  On 10-Jun-2022, the vaccination facility was made aware of administration of vaccines beyond use date after the thaw process while audit was conducted. Patient got Moderna with vaccine Ndc code 80777-0273-99. The Clinic date was reported as 09 Jan 2022. Patient had reported no adverse reactions after the administration of vaccine.  No treatment medication were reported.
Information has been received from a physician concerning a 6 year old male with a family history of asthma who on approximately 01-JUN-2007 was vaccinated with a dose of Vaqta. Suspect vaccination on the same day included a dose of Varivax. On approximately 01-JUN-2007, after vaccination the patient experienced dizziness and respiratory distress while leaving the office. The patient returned to the office and was given a breathing treatment and Prednisone. At the time of report, the patient had recovered. A product quality complaint was not involved. The patient's experiences were considered to be other important medical events by the reporter. Additional information has been requested.
SOB a few days after vaccination; one week later, new onset of acute exacerbation of HFrEF with subsequent respiratory failure and hospitalization
8/13/00, erythema, induration, warmth and vesicular eruptions noted 2cm around site.
Lump and swelling of lymph nodes under left armpit, with tenderness.  Small lump noticed the size of a marble and seems to have gotten bigger particularly after the second dose of the vaccine that was received on June 14th. still has swelling and tenderness in that area.
I was mistakenly given six doses of the vaccine.  So far symptoms include: headache and site pain
Within 4 hours: extreme fatigue, headache, loose stools continued until 8am 3/7/2021. Itching all over body, without hives, from 2pm 3/7/2021 until 6:45pm 3/7/2021 - unsure itching is over.
Date Event 2021-03-14 Covid vaccine Pfizer EN6207  2021-04-06 Covid vaccine Pfizer EW0150 2021-11-15 Covid Booster Pfizer Lot FD0809 2022-01-03 Graves disease episode onset manifested by aggitation, 120 bpm pulse, irregular heart rate; successfully treated with methimazole and beta blocker. However, for appoximately 3 weeks after treatment began, had a complete shutdown consisting of brain fog, dizziness, inertia. After emerging had to "relearn" various skills that had been in place for 20 years.  2023-01-14 Continue treatment of 2022-01-03 episode. Am hoping for a remission.   Initial onset of Graves disease 1996 diagnosed with  radioactive iodine uptake and scan. Since that time I have had short episodes treated successfully with methimozole for about 12 weeks or less followed with remission. Was already taking a beta blocker for migraine in the earlier years.  However, the 01-03-2022 episode has been dramatically different and is still on-going after more than a year.  The difference is the duration and the dramatic difference in symptoms, including the bodily shutdown for just under 3 weeks.   Also new is the tree nut allergy to pecans and walnuts  triggering vestibular/syncopal migraine.   2021-10-01 Vestibular/syncopal migraine triggered by pecans. Within months walnuts would be added to list.
flu like symptoms, chills, fever, aches, headache, nausea, dizziness, arm red and swelling
Patient was administered two doses of Pfizer Biontech Covid 19 bivalent vaccine. Patient had no adverse reactions.
Red, raised, hard, itchy circle around injection site.  Started one day after injection.  Went away and came back one week after injection.
I do have asthma and allergies, but I was coughing more than normal. My wife is dealing with some medical things and so I thought I would take a COVID-19 test just to be sure since I did not want to put her at risk and, I was positive. I did reach out to my doctor that same day and he did offer me Paxlovid but I decided not to take it. I have really only had a cough that is similar to what I would have with my allergies. This past Tuesday the 2nd I did test negative. I happened to have my static nerve act up during this but other than the cough I have not had symptoms. I did get a flu shot the same day I got my COVID-19 vaccine but do not have the information.
Rapid onset severe Vertigo upon waking in middle of night 10 days following 1st dose.  No history of chronic Vestibular disease , however do have history of period right "swimmers ear"  Severe balance issues standing/walking and clockwise rotational vision upon initial presentation to 24 hours.  Condition improved to moderate balance issues and moderate clockwise rotation vision issues at 48 hours.  Symptoms subsided over the course of first week to no vision issues, but slight balance issues.    Symptoms have improved at Day 14 to very low level of slight imbalance.  Freeway driving uncomfortable.  Kaiser nurse consult at 10 hours, physician phone consult at 80 hours after presentation, diagnosed Vertigo.
vaccine exposure during pregnancy with no reported adverse event; Initial information received on 23-Sep-2022 regarding an unsolicited valid  non-serious case received from a other health professional.  This case involves a 28 years old female patient who was exposed to vaccine Influenza quadrival A-B vaccine [Fluzone QIV] in context of vaccine exposure during pregnancy with no reported adverse event.  Data regarding this pregnancy were received prospectively, i.e. before pregnancy outcome was known. The reported vaccine exposure during pregnancy with no reported adverse event occurred at unknown gestation period.  The date of last menstrual period was not reported. The estimated due date is 26-Feb-2023. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. The patient had no previous pregnancy/ies.   On 22-Sep-2022, the patient received a dose 1 of suspect Influenza quadrival A-B vaccine, suspension for injection (lot UT7682KA; strength and expiry date not reported) via unknown route in the left deltoid for prophylactic vaccination.  On 22-SEP-2022 the patient had vaccine exposure during pregnancy with no reported adverse event (exposure during pregnancy) (latency; on same day). Relevant prenatal testing after exposure was not reported.  Action taken : not applicable.  At time of reporting, the outcome was Unknown for the event vaccine exposure during pregnancy with no reported adverse event.  Additionally, at time of reporting, the pregnancy is still ongoing.
Pt received vaccines around 1400 on 1/30/14. 1/31/14 pt woke up with fever and maintained a fever of 102 most of the day. Pt has no other symptoms of concern. Decreased appetite and activity.
This spontaneous report as received from a registered nurse refers to a patient of unknown demographics. No concurrent conditions or medical history were provided. On 03-JUN-2013, the patient was vaccinated with the first dose of RECOMBIVAX HB 2.5/0.5 (units not provided) injection, administered intramuscularly at a dose of 0.5 ml (indication, lot# and expiry date unspecified), then with the second dose on 17-SEP-2013 and with the third dose on 10-JAN-2014. No concomitant medications were reported. No adverse effects were reported. Additional information is not expected as the reporting nurse did not grant permission to contact her.
28JUL97 pt exp SOB, & minor assoc cough, chest pain;pt dx hypersensitivity pneumonitis;pt later dx cardiomyopathy of unk origin;exp sarcoid or other such immune-related issues;dx cardiomyopathy unk origin secondary dx HTN, pneumonitis;
J96.00 ACUTE RESPIRATORY FAILURE 4/12/2021 CKD STAGE 4 (GFR 15-29)
On Sunday (2/23/03) mom noticed small pox like rash on infants face - looked and found more at site of varicella vaccination. No temp noted. Child's appetite is off, otherwise is playing and normal. now has rash on face, legs and arms.
other arm is hurting as well/ opposite arm of injection started hurting; injection arm hurting; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A 22 year-old female patient received bnt162b2 (BNT162B2), administered in arm left, administration date 29Sep2021 (Batch/Lot number: unknown) as dose 1, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: VACCINATION SITE PAIN (non-serious) with onset 29Sep2021, outcome "unknown", described as "injection arm hurting"; PAIN IN EXTREMITY (non-serious) with onset 30Sep2021, outcome "not recovered", described as "other arm is hurting as well/ opposite arm of injection started hurting".  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
The patient received a 2nd dose of bivalent Moderna vaccine without  clarification or verification of any chronic illnesses or immunocompromised or weakened immune sysytem. The PQCF was filled out in a foreign language.
Blood clot on right calf 20 hours after 1st dose of Pfizer Covid-19 vax; Flash nerve pains (sharp burning) for the next 16 months; swollen & painful thyroid;
I did not have an adverse reaction to the vaccine but I tested positive COVID-19 on 06/13/2022.  I did the home test for COVID-19. Contacted my primary health provider and they prescribed Lagevrio.  My symptoms where fatigue and congestion.
Pt called on 8/21/08 to report that following the administration of 2nd Hep A & Hep B vaccine, she was fine until the next morning. She then began running a fever and having flu-like symptoms. Developed hives from head to toe. Has had prior hx of hives but has not had them in several years. Was in the process of being treated by the family physician utilizing steroids. Pt's only other reaction to a vaccine was the oral typhoid in which she experienced diarrhea and stomach cramping.
COVID-19 confirmed by positive COVID-19 test; COVID-19 confirmed by positive COVID-19 test; This is a spontaneous report received from a contactable consumer (patient). This 51 years old female received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) the first single dose on 31Mar2021 (lot EN6199) in left arm and the second single dose on 21Apr2021 (lot ER8737), both at 51 years of age, for COVID-19 immunisation. Relevant medical history, family history and concomitant medications were none. She had no problems with unspecified shots in the past. The patient had her second dose of the Pfizer COVID 19 vaccine and tested positive on 14May2021 (she got the results on 15May2021). Testing was swabbed from mouth. Her 16 years old teenage daughter turned out to be positive for COVID so she got tested. She didn't have any symptoms at that time, but right now she had like a cold. The patient added that she lost her smell. The event required physician office visit. She was not hospitalized. The event did not require any treatment or ER visit or hospitalization. She did not display clinical signs at rest indicative of severe systemic illness. The event did not result in multiorgan failure, respiratory diseases, cardiovascular diseases, gastrointestinal/hepatic diseases, renal diseases, neurological diseases, hematological diseases or dermatological diseases. COVID-19 was resolving.
Child given flu shot left deltoid region, several minutes later complaining of numbness left forearm and tingling of hand.  Examined by Dr, no abnormal neuro exam, child saying felt much better after 30 minutes and sent home.  Motrin for pain.
Itching Injection Site; Big rash on injection site; Hot to the touch Injection Site; Red Injection Site; Injection Site was hurting again; Pain Injection Site/; Discomfort Injection Site; This spontaneous case was reported by a consumer and describes the occurrence of INJECTION SITE PAIN (Pain Injection Site/), INJECTION SITE DISCOMFORT (Discomfort Injection Site), INJECTION SITE PRURITUS (Itching Injection Site), INJECTION SITE RASH (Big rash on injection site) and INJECTION SITE WARMTH (Hot to the touch Injection Site) in an 83-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 16-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 16-Jan-2021, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 16-Jan-2021, the patient experienced INJECTION SITE PAIN (Pain Injection Site/) and INJECTION SITE DISCOMFORT (Discomfort Injection Site). On 23-Jan-2021, the patient experienced INJECTION SITE PRURITUS (Itching Injection Site), INJECTION SITE RASH (Big rash on injection site), INJECTION SITE WARMTH (Hot to the touch Injection Site), INJECTION SITE ERYTHEMA (Red Injection Site) and INJECTION SITE PAIN (Injection Site was hurting again). On 27-Jan-2021, INJECTION SITE PRURITUS (Itching Injection Site), INJECTION SITE WARMTH (Hot to the touch Injection Site), INJECTION SITE ERYTHEMA (Red Injection Site) and INJECTION SITE PAIN (Injection Site was hurting again) had resolved. At the time of the report, INJECTION SITE PAIN (Pain Injection Site/), INJECTION SITE DISCOMFORT (Discomfort Injection Site) and INJECTION SITE RASH (Big rash on injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) and mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Treatment details included Tylenol , Advil, and Cold Compress. No concomitant medications were provided by reporter.
Patient presented to the vaccine clinic for her second covid vaccine. Staff outside had not verified date of first vaccine, when I went to document and verify patients first dose patient advised that she received the first dose on 01/16/2021. Then verified with management that patient was to early for her second dose as it has only been 20 days.
This spontaneous report was received from a physician refers to a 60 year old female patient. On an unknown date(reported as in last 3 months), the patient was vaccinated with ZOSTAVAX, (lot number, expiry date and route was not reported). Concomitant medications were not reported. On an unknown date, after 3 or 4 days the patient experienced pain at injection site and a reaction described as egg shaped lesion like after tetanus vaccination. The outcome of the events were reported as recovering. Additional information has been requested.
2nd day fever, chills, sleepy.  The next week on 4/8 I had burning sensation on leg and hip left side.  I was diagnosed with shingles 2 days later .
This case was reported by a consumer via call center representative and described the occurrence of pain in arm in a 76-year-old male patient who received Shingrix for prophylaxis. Previously administered products included Zostavax. On 1st August 2018, the patient received the 1st dose of Shingrix (intramuscular). In August 2018, less than a month after receiving Shingrix, the patient experienced pain in arm and influenza-like symptoms. On an unknown date, the outcome of the pain in arm and influenza-like symptoms were recovered/resolved. It was unknown if the reporter considered the pain in arm and influenza-like symptoms to be related to Shingrix. Additional details reported as follows: The reporter was the patient's wife. The patient received Shingrix on left arm. The reporter stated the patient experienced sore arm and flu like symptoms which lasted for total of 3 to 4 days. No further details were provided by the reporter. This case has been linked with US2018149412, reported by same reporter for herself.
Patient had massive heart attack, lost consciousness and hit his head as he fell. Patient had pain in his left arm approximately 5 days before the event. on 6/16/2021 patient lost consciousness again, this time due to low blood pressure. the low blood pressure was said to be due to dehydration.
Increased heart rate and blood pressure. Rash on anterior right side of neck. She laid down and was given water. Blood pressure and heart rate monitored. She was also reassured by friends that she was okay. The patient said she was anxious and that's why she had a reaction.
The patient developed symptoms of pneumonia 2 days after receiving shot and was admitted to the hospital for pneumonia 3 days following the shot.
I was asked to report my case of complex appendicitis which resulted in an emergency appendectomy.
Her mouth didn't feel right; looking now at her upper lip and it has started to swell; Her mouth is starting to swell; Her jaw was swelling; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non-healthcare professional) from medical information team. The reporter is the patient. Other Case identifier(s): US-PFIZER INC-202101301557 (Pfizer). A 92-year-old female patient received bnt162b2 (BNT162B2), administration date 01Oct2021 11:30 (Lot number: EW0186) at the age of 92 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "arthritis" (unspecified if ongoing), notes: Her knees were kind of in pain prior to vaccination. Concomitant medication(s) included: TYLENOL taken for arthritis. Vaccination history included: Bnt162b2 (1st dose) for Covid-19 immunisation, Bnt162b2 (2nd dose) for Covid-19 immunisation. The following information was reported: ORAL DISCOMFORT (non-serious) with onset 01Oct2021, outcome "unknown", described as "Her mouth didn't feel right", LIP SWELLING (non-serious) with onset 01Oct2021, outcome "unknown", described as "looking now at her upper lip and it has started to swell", MOUTH SWELLING (non-serious) with onset 01Oct2021, outcome "unknown", described as "Her mouth is starting to swell", SWELLING FACE (non-serious) with onset 01Oct2021, outcome "unknown", described as "Her jaw was swelling".  Additional information: The patient had her booster or third dose of the Pfizer COVID-19 vaccine today at 11:30 am and was wearing a mask. When removed the mask, her mouth didn't feel right and noticed that her upper lip was swelling and mouth started to swell. Caller stated that she looks like someone hit her in the upper lip and mouth. Caller was looking at her face and on the left side of her face, her jaw was swelling a little and she is in the house by herself. Caller also stated that she took small amount of peanut butter and 2 Tylenol for her arthritis as her knees were kind of in pain prior to vaccination. Caller wanted to know if this had been reported side effect with the Pfizer COVID-19 vaccine and what she should do about it.  Follow-up attempts are completed. No further information is expected.
This case was reported by a pharmacist via call center representative and described the occurrence of shingles in a 84-year-old female patient who received SHINGRIX (batch number 9NJ59, expiry date 8th February 2021) for prophylaxis. Co-suspect products included SHINGRIX for prophylaxis. Concomitant products included Valacyclovir. On 24th August 2018, the patient received the 1st dose of SHINGRIX. On an unknown date, the patient received the 2nd dose of SHINGRIX. On an unknown date, less than a year after receiving SHINGRIX and not applicable after receiving SHINGRIX, the patient experienced shingles and inappropriate schedule of vaccine administered. On an unknown date, the outcome of the shingles and inappropriate schedule of vaccine administered were unknown. It was unknown if the reporter considered the shingles to be related to SHINGRIX. Additional details were provided as follows: The reported batch number for SHINGRIX was 9N559, which was changed to 9NJ59, as per sales data sheet. The patient developed Shingles after the first dose of SHINGRIX. No additional details were reported.